NZ589033A - Novel polymorphs of azabicyclohexane - Google Patents

Abstract

The disclosure relates to a composition comprising an acid addition salt of (+)-I-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane enriched for a selected polymorphic form of said acid addition salt of (+)-1-(3 ,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane selected from: Polymorph A, Polymorph B and Polymorph C, each exhibiting an X-ray powder diffraction pattern as measured at crystal sizes of from about 10 to 40 microns characterized by distinguishing peaks at one or more of and at about the 2-theta (degree) values defined in the specification. Also disclosed is a process for producing said Polymorph A, Polymorph B and Polymorph C.

Description

New Zealand Paient Spedficaiion for Paient Number 589033 Patent Form No. 5 NEW ZEALAND Patents Act 1953 COMPLETE SPECIFICATION DIVISIONAL OF NEW ZEALAND PATENT APPLICATION 553337 TITLE: NOVEL POLYMORPHS OF AZABICYCLOHEXANE We Dov Pharmaceutical, Inc. a US company of 150 Pierce Street, Somerset, New Jersey, 08873, United States of America, do hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement: 4003q NOVEL POLYMORPHS OF AZABICYCLOHEXANE The present application is a divisional application from New Zealand patent application number 553337, the entire disclosure of which is incorporated herein by reference.

This application claims priority to United States Patent Application Serial No. 10/920,748, filed August 18, 2004, which is converted to a provisional application.

Salts of the (+) isomer of phenyl azabicyclohexane having the formula are known for use in treating depression. As set forth in Lippa et al,, U.S. Patent No. 6,372,919, the compound of formula I whose chemical name is (+)-l-(3, 4-dichlorophenyl)-3~azabicycto[3,1 .Ojhexane in its (+) isomeric form has been found to have potent anti-depressive activity.

While the azabicyclohexanes of formula I have been prepared as described in various U.S. patents such as U.S. Patents 4,231,935, 4,131,611,4,435,419, 4,118,417 and 4,196,120, these compounds were prepared in racemic form. In the procedure of Lippa et al., U.S. Patent No. 6.372,919, the (+) optical antipode was produced as a mixture of various isomeric polymorphic forms which heretofore have been unrecognized. A pure crystalline form of the (+) isomer of the compound of formula I is of particular importance since it could be formulated into various pharmaceutical dosage forms such as for example tablets or capsules for treatment of patients. Variations in crystal structure of a pharmaceutical drug substance are known to affect the dissolution, manufacture, stability and bioavailability of a pharmaceutical drug product, particularly in solid oral dosage forms. Therefore it is important to produce the (+) isomer of the compound of formula I in a pure form comprising a single therrnodynamically stable crystal structure. la Received at IPONZ on 04/05/2012 The discussion of documents, acts, materials, devices, articles and the like is included in this specification solely for the purpose of providing a context for the present invention. It is not suggested or represented that any or all of these matters formed part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed 5 before the priority date of each claim of this application.

Where the terms "comprise", "comprises", "comprised" or "comprising" are used in this specification (including the claims) they are to be interpreted as specifying the presence of the stated features, integers, steps or components, but not precluding the presence of one or more other features, integers, steps or components, or group thereof.

SUMMARY OF INVENTION In accordance with this invention, it has been discovered that the (+) optical antipode of the compound of formula 1 as prepared in Lippa et al., U.S. Patent 6,372,919 5 exists as a mixture of two crystalline polymorphic structures, one being the 15 hemi-hydrate form, which is designated as polymorph form A, and the other being the anhydrous form, which is designated as polymorph form B. A dehydrated form designated as polymorph form C has also been found. When the (+) optical antipode of the compound of formula I is produced by prior art procedures, it has been found that it was produced as a mixture of polymorph form A and polymorph form B which do not 20 readily separate into their pure polymorphic crystalline forms.

In accordancc with this invention, a method of forming these polymorphs as pure independent polymorph forms has been discovered. In addition we have found that the polymorph form A of the (+) optical antipode of the compound of formula I in its pure crystalline structure produced in accordance with this invention is a 25 therrnodynamically stable polymorph form. Therefore, form A is the preferred crystalline form of the (+) optical antipode of the acid addition salt of the compound of formula I for formulation into pharmaceutical drug products.

In one aspect, the present invention provides a composition comprising an acid addition salt of (+)-l-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane enriched for a selected 30 polymorphic form of said acid addition salt of (+)-l-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0 Jhexane selected from: 2 Received at IPONZ on 04/05/2012 Polymorph A exhibiting an X-ray powder diffraction pattern as measured at crystal sizes of from about 10 to 40 microns characterized by distinguishing peaks at one or more of and at about the following °20 (degree) values: 17.14 19.62 21.96 24.52; and 26.74 Polymorph B exhibiting an X-ray powder diffraction pattern as measured at crystal sizes of from about 10 to 40 microns characterized by distinguishing peaks at one or more of and at about the following °20 (degree) values: .58 17.52 21.35 23.04 .43; and 30.72; and Polymorph C exhibiting an X-ray powder diffraction pattern as measured at crystal sizes of from about 10 to 40 microns characterized by distinguishing peaks at one or more of and at about the following °20 (degree) values: 13.34 17.64 20.07 21.32 22.97 24.86. 26.32; and 27.90, wherein said composition is enriched to contain at least 70-80% of said Polymorph A, Polymorph B, or Polymorph C, by weight.

In a further aspect, the present invention provides a composition comprising an acid addition salt of (+)-l -(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane enriched for a selected polymorphic form of said acid addition salt of (+)-1 -(3,4-dichlorophenyl)-3 - azabicyclo[3.1 .OJhexane selected from: Polymorph A exhibiting a Raman spectrum characterized by distinguishing peaks at one or more of and at about the following wavenumbers (cm-1): 762; 836; 921; 959; 2a RECEIVED at IPONZ on 18 May 2012 1393 1597 2890 2982 3064 and Polymorph B exhibiting a Raman spectrum characterized by distinguishing peaks at one or more of and at about the following wavenumbers (cm-1): 1245 1380 2963 2993 3027; and 3066; and Polymorph C exhibiting a Raman spectrum characterized by distinguishing peaks at one or more of and at about the following wavenumbers (cm-1): 1059 1094 1266 1343 1595 2966 2900; and 3070, wherein said composition is enriched to contain at least 70-80% of said Polymorph A, Polymorph B, or Polymorph C, by weight.

DETAILED DESCRIPTION OF THE INVENTION In accordance with this invention, it has been discovered that the (+) optical antipode of acid addition salts of the compound of formula I exists in three different crystalline polymorphic forms designated as polymorph form A, polymorph form B and 30 polymorph form C and that polymorph form A, which is the hemi-hydrate form, is a therrnodynamically stable form.

Polymorph form A may be characterized as the hemi-hydrate of acid addition salts of (+)-1 -(3,4-dichlorophenyl)-3 -azabicyclo[3.1 ,0]hexane. It is the hemi-hydrate crystalline form, which uniquely characterizes polymorph form A from polymorph form 35 B and polymorph form C of acid addition salts of the compound of formula I.

Polymorph form B and polymorph form C of acid addition salts of (+)-l-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane do not exist as hemi-hydrates.

The polymorphs of acid addition salts of (+)-l-(3,4-dichlorophenyI)-3-azabicyclo[3.1.0]hexane may also be characterized by their X-ray powder diffraction 40 patterns (XRPD) and/or their Raman spectroscopy peaks. With respect to X-ray powder 2b Received at IPONZ on 04/05/2012 from said solvent under anhydrous conditions at temperatures of from about 50°C to 85°C said polymorph form B in crystalline form.

In a further aspect, the present invention provides a method of producing polymorph form C of an acid addition salt of (+) - 1- (3, 4-dichlorophenyl)-3azabicyclo [3.1.0] hexane in crystalline form substantially free of other geometric, optical and polymorphic isomers thereof comprising heating a solid containing one or more polymorphs of the acid addition salt of (+) - 1- (3, 4-dichlorophenyl)-3-a/.abicyclo [3.1.0] hexane other than polymorph form C to a temperature of at least 50°C until said polymorph form C in crystalline form is produced.

In a further aspect, the present invention provides a pharmaceutical composition in oral unit dosage form comprising solid polymorph form A of a pharmaceutically acceptable acid addition salt of (+) - 1- (3, 4-dichlorophenyl)-3-azabicyclo [3.1.0] hexane in crystalline form substantially free of other geometric, optical and polymorphic isomers thereof and an inert pharmaceutically acceptable carrier or diluent.

In a further aspect, the present invention provides a pharmaceutical composition in oral unit dosage form comprising solid polymorph form B of a pharmaceutically acceptable acid addition salt of (+) - 1- (3, 4-dichlorophenyl)-3-azabicyclo [3.1.0] hexane in crystalline form substantially free of other geometric, optical and polymorphic isomers thereof and an inert pharmaceutically acceptable carrier or diluent.

In a further aspect, the present invention provides a pharmaceutical composition in oral unit dosage form comprising solid polymorph form C of a pharmaceutically acceptable acid addition salt of (+) - 1- (3, 4-dichlorophenyl)-3-azabicyclo [3.1.0] hexane in crystalline form substantially free of other geometric, optical and polymorphic isomers thereof and an inert pharmaceutically acceptable carrier or diluent.

In a further aspect, the present invention provides use of a composition containing polymorph form A of a pharmaceutically acceptable acid addition salt of (+) - 1- (3, 4-dichlorophenyl)-3-azabicyclo [3.1.0] hexane in crystalline form substantially free of other geometric, optical and polymorphic isomers thereof and an inert carrier or diluent for the manufacture of a medicament for the prevention or treatment of depression in a patient in need of said treatment comprising administering to said patient in an effective amount.

In a further aspect, the present invention provides use of a composition 2c Received at IPONZ on 04/05/2012 containing polymorph form B of a pharmaceutically acceptable acid addition salt of (+) - 1- (3, 4-dichlorophenyl)-3-azabicyclo [3.1.0] hexane in crystalline form substantially free of other geometric, optical and polymorphic isomers thereof and an inert carrier or diluent for the manufacture of a medicament for the prevention or treatment of depression in a patient in need of said treatment comprising administering to said patient in an effective amount.

In a further aspect, the present invention provides use of a composition containing polymorph form C of a pharmaceutically acceptable acid addition salt of (+) - 1- (3, 4-dichlorophenyl)-3-azabicyclo [3.1.0] hexane in crystalline form substantially 10 free of other geometric, optical and polymorphic isomers thereof and an inert carrier or diluent for the manufacture of a medicament for the prevention or treatment of depression in a patient in need of said treatment comprising administering to said patient in an effective amount.

In a further aspect, the present invention provides a pharmaceutical composition 15 comprising a mixture of polymorph form A and either or both polymorph form B and polymorph form C of a pharmaceutically acceptable acid addition salt of (+) -1- (3, 4-dichloro)-3-azabicyclo [3.1.0] hexane.

In a further aspect, the present invention provides a pharmaceutical composition comprising a mixture of polymorph form B and either or both polymorph form A and 20 polymorph form C of a pharmaceutically acceptable acid addition salt of (+) -1- (3, 4-dichloro)-3-azabicyclo [3.1.0] hexane.

In a further aspect, the present invention provides a pharmaceutical composition comprising a mixture of polymorph form C and either or both polymorph form A and polymorph form B of a pharmaceutically acceptable acid addition salt of (+) -1- (3, 4-25 dichloro)-3-azabicyclo [3.1.0] hexane.

DETAILED DESCRIPTION OF THE INVENTION In accordance with this invention, it has been discovered that the (+) optical antipode of acid addition salts of the compound of formula I exists in three different 30 crystalline polymorphic forms designated as polymorph form A, polymorph form B and polymorph form C and that polymorph form A, which is the hemi-hydrate form, is a therrnodynamically stable form. 2d Received at IPONZ on 04/05/2012 Polymorph form A may be characterized as the hemi-hydrate of acid addition salts of (+)- 1 -(3,4-dichlorophenyl)-3 -azabicyclo[3.1 .OJhexane. It is the hemi-hydrate crystalline form, which uniquely characterizes polymorph form A from polymorph form B and polymorph form C of acid addition salts of the compound of formula I. Polymorph form B and polymorph form C of acid addition salts of (+)-l-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane do not exist as hemi-hydrates.

The polymorphs of acid addition salts of (+)-1 -(3,4-dichlorophenyl)-3 -azabicyclo[3.1.0]hexane may also be characterized by their X-ray powder diffraction patterns (XRPD) and/or their Raman spectroscopy peaks. With respect to X-ray powder diffraction, the relative intensities of the X-ray powder diffraction peaks of a given polymorph may vary depending upon the crystal size of the polymorph used to determine the pattern. This is a phenomenon of preferred orientation. Preferred orientation is caused by the morphology of crystals. In this case, the XRPD analysis should be carried out with 5 the sample spinning in the sample holder during XRPD analysis to reduce the preferred orientation effects. Samples for XPRD analysis for determination of the presence and nature of their polymorph status in accordance with this invention should be lightly ground and/or sieved to a crystal size of from about 10 to 40 microns for XPRD analysis.

A Bragg-Brentano instrument, which includes the Shimadzu system, used for the 10 X~ray powder diffraction pattern measurements reported herein, gives a systematic peak shift (all peaks can be shifted at a given "°20" angle) which result from sample preparation errors as described in Chen et al.; J Pharmaceutical and Biomedical Analysis, 2001; 26, 63. Therefore, any "°20" angle reading of a peak value is subject to an error of about (±) 0.2°.

The X-ray powder diffraction pattern (XRPD) analyses of polymorph forms A, B and C were performed with a Shimadzu XRD-6000 X-ray powder diffractometer using Cu Ka radiation. In this procedure the compound as a hydrochloride salt was loaded onto the machine as a crystalline powder. The instrument was equipped with a long fine focus X-ray tube. The tube voltage and amperage were set to 40 kV and 40 mA, respectively. The 20 divergence and scattering slits were set at 1° and the receiving slit was set at 0.15 mm. Diffracted radiation was detected by a Nal scintillation detector. A theta-two theta continuous scan at 3°/min (0.4 sec/0.02° step) from 2.5 to 40 Q29 was used. A silicon standard was analyzed to check the instrument alignment. Data were collected and analyzed using XRD-6000 v. 4.1.

The following Table 1 shows the peaks of the X-ray powder diffraction pattern of purified polymorph form A of the hydrochloride salt of (+)-l-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane having a crystal size of from about 10 to 40 microns. This pattern is given in terms of the "°28" angles of the peaks subject to the angle error set forth above. With respect to the percent value of relative intensity (I/lo) given in Table 1, Io 30 represents the value of the maximum peak determined by XRPD for the sample for all "°20" angles and I represents the value for the intensity of a peak measured at a given "°20" angle", The angle "°28" is a diffraction angle which is the angle between the incident X-rays and the diffracted X-rays. The values for the relative intensities for a 3 given peak set forth in percent and the "°20" angles where said peaks occur are given in Table 1 below.

Table I XRPD Peaks (°29) and Relative Intensities (l/lo) for Polymorph Form A Form A °2 e I/lo °2Q i/lo 4.55 33.42 9 9.10 34.24 6 13.65 6 .08 17.14 60 .65 16 37.85 11 36.31 14 18.24 23 37.11 26 18.49 14 37.78 9 19.27 14 39.85 9 19.62 22 21.74 21,96 100 22.24 12 23.01 7 24.52 43 24.79 26.74 52 27,44 11 27.63 17 28.36 16 28.48 26 29,00 14 29.20 19 29.40 27 29.57 27 .24 18 31,01 13 31.62 17 32,20 24 32.93 12 4 The following Table 2 shows the peaks of the X-ray powder diffraction pattern of purified polymorph form B of the hydrochloride salt of (+)-l-(3,4-dichloropheny!)-3-azabicyclo[3.1.0]hexane having a crystal size of from about 10 to 40 microns. The values for the relative intensities for a given peak set forth in percent and the "°20" angles where 5 said peaks occur for polymorph form B of the hydrochloride salt of (+)-l-(3,4- dichlorophenyl)-3-azabicyclo[3.1.0]hexane having a crystal size of about 10 to 40 microns are given in Table 2 below.

Table 2 XRPD Peaks (°29) and Relative Intensities (l/lo) for Polymorph Form B Form B "2d 1 l/(o °2$ i/lo .50 6 32.14 13.34 12 32.31 7 .58 42 32.80 7 17.12 6 32.95 6 17.36 8 33.45 44 17.52 26 33.74 12 18.21 11 .25 .40 7 .40 12 21.35 97 .58 9 21.61 17 36.75 8 21.93 11 37.55 18 22.64 6 39.01 23.04 79 39.22 7 24.09 6 39.37 7 . 24.52 14 39.86 11 .43 96 26.24 53 26.36 73 26.75 11 26.88 7 27.44 6 27.94 12 28.36 28.54 29.39 29.72 9 ' 30.07 7 .58 8 .72 100 I 31.07 14 31.38 12 31.55 7 31.78 12 The following Table 3 shows the peaks of the X-ray powder diffraction pattern of purified polymorph form C of the hydrochloride salt of (+)-l-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane having a crystal size of from about 10 to 40 microns. The values for the relative intensities for a given peak set forth in percent and the "°29" angles where 5 said peaks occur for polymorph form C of the hydrochloride salt of (+)-l -(3,4- dichlorophenyl)-3-azabicyclo[3.1.0]hexane having a crystal size of about 10 to 40 microns are given in Table 3 below.

Table 3 XRPD Peaks (°20) and Relative Intensities (Vlo) for Polymorph Form C Form C "26 I/lo "20 l/io ,46 6 27.90 54 .66 28.14 8 6.37 6 28.56 32 7.26 6 28.74 17 8.75 6 29.20 6 13.34 29.72 6 13.94 11 29.92 26 .65 7 .54 13 16.26 7 .72 19 17.01 8 .96 31 17.38 9 31.42 7 17.64 83 31.68 11 17.92 31.80 18.23 40 31.97 6 19.08 7 32.43 21 19.38 46 33.26 12 19.86 33.40 .07 100 33.64 21.16 17 33.84 18 21.32 94 34.11 IS 21.64 37 34.70 11 22.42 .07 8 22.70 12 .64 11 22.97 70 .91 8 23.31 6 36.09 21 24.09 37.80 12 24.86 94 38.06 6 .24 32 38.17 6 .38 49 39.04 6 26.12 13 39.23 8 26.32 90 39.77 7 26.87 18 27.21 39 However, there are key major peaks at given angles in these X-ray powder diffraction patterns which are unique to each given polymorph form. These peaks are present in the XRPD patterns of each of the polymorph forms having a crystal size of 6 about 10 to 40 microns. Any of these major peaks, either alone or in any distinguishing combination, are sufficient to distinguish one of the polymorph forms from the other two polymorph forms. For polymorph form A, the "°2Q" angles of these major peaks which characterize polymorph form A, subject to the error set forth above, are as follows; 17.14; 19.62; 21.96; 24.52; and 26.74.

Any of these major peaks, either alone or in any distinguishing combination, are sufficient to distinguish polymorph form A from the other two polymorph forms.

Also, there are key major peaks at given angles in the XRPD of polymorph form B 15 which are unique to polymorph form B as the hydrochloride salt having a crystal size of about 10 to 40 microns that are typically present in the XRPD pattern of polymorph form B as the hydrochloride salt irrespective of the particle size. Any of these major peaks, either alone or in any distinguishing combination, are sufficient to distinguish polymorph form B from the other two polymorph forms. For polymorph form B, the "°20" angles of 20 these major peaks which characterize polymorph form B, subject to the error set forth above, are as follows: .58; 17.52; 21.35; 23.04; .43; and .72.

Also, there are key major peaks at given angles in the XRPD of polymorph form C 30 which are unique to polymorph form C as the hydrochloride salt, having a crystal size of about 10 to 40 microns, that are typically present in the XRPD pattern of polymorph form C as a hydrochloride salt irrespective of the particle size. Any of these major peaks, either alone or in any distinguishing combination, are sufficient to distinguish polymorph form C from the other two polymorph forms. For polymorph form C, the "°20" angles of these 35 major peaks which characterize polymorph form C, subject to the error set forth above, are as follows: 13.34; 17.64; 7 .07 21.32 22.97 24.86 26.32 and 27.90.

Another method of characterizing the three polymorphs of (+)-l-(3,4-dichlorophenyl)-3-azabicyclo[3,1.0]hexane is through Raman spectroscopy. The 10 procedure for carrying out Raman Spectroscopy is described on pages 260-275 of Skoog and West, Principles of Instrumental Analysis (2nd Ed.); Saunders College, Philadelphia (1980).

Briefly, Raman spectra were obtained using a FT-Raman 960 (or 860) spectrometer (Thermo Nicolet) interfaced to an 860 FT-IR. This spectrometer uses an 15 excitation wavelength of 1064 nm. Approximately 0.912 W of Nd:YV04 laser power was used to irradiate the samples. The Raman spectra were measured with an indium gallium arsenide (InGaAs) detector. The samples were pressed into pellets for analysis. A total of 128 sample scans were collected from 3600 or 3700 - 98 cm'1 at a spectral resolution of about (±) 4 cm'1, using Iiapp-Genzel apodization. Wavelength calibration was performed 20 using suLfur and cyclohexane, The Raman spectra peak positions given below in wavenumbers (cm"') for the purified polymorph forms A, B and C of the hydrochloride salt of (+)-l-(3,4-dichlorophenyl)-3-azabicyclo[3.1,0]hexane are subject to an error of about (±) 4 cm"1.

The Raman spectra peak positions in wavenumbers (cm"1) for polymorph form A 25 of the hydrochloride salt of (-i-)-l-(3,4-dichloropbenyI)~3~azabicyclo[3.1 .Ojhexane are given in Table 4. 8 Table 4 Raman Peak Listing for Polymorph Form A (peaks> 400 cm"1) Peak Positions In Wavenumbers (cm"1) Form A 436 1135 479 1189 534 1229 549 1274 646 1309 691 1338 680 1366 762 1393 812 1453 836 1484 892 1557 921 1597 959 2890 982 2969 998 2982 1030 3017 1056 3046 1099 3064 1122 The Raman spectra peak positions in wavenumbers (cm-1) for polymorph form B 25 of the hydrochloride salt of (+)-l-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane are listed in Table 5.

Table 5 Raman Peak Listing for Polymorph Form B (peaks> 400 cm"1) 30 Peak Positions In Wavenumbers (cm"1) Form A 418 1245 446 1278 478 1309 533 1343 648 1380 676 1398 686 1456 767 1483 825 1557 852 1593 895 2895 964 2963 979 2993 i 031 3027 1054 3066 1070 1099 1136 i 189 9 The Raman spectra peak positions in wavenumbers (cm"1) for polymorph form C of the hydrochloride salt of (+)-l -(3,4-dichlorophenyl)-3-azabicyclo[3.1 .Ojhexane are given in Table 6.

Table 6 Raman Peak Listing for Polymorph Form C (peaks> 400 cm"1) Peak Positions In Wavenumbers (cm'1) Form C 441 1246 474 1266 532 1279 648 1309 674 1343 690 1398 767 1456 811 1471 826 1557 856 1595 895 2900 970 2966 103! 2992 1059 3048 1094 3070 1122 1137 1189 1228 | PCT/U S2005/029420 Table 4, Table 5 and Table 6 provide the complete patterns of the Raman peak positions with respect to the hydrochloride salts of polymorph forms A, B and C respectively. However, there are certain key peaks, within these patterns, which are unique to each of the hydrochloride salts of these polymorphs. Any of these key peaks, either alone or in any distinguishing combination, are sufficient to distinguish one of the polymorph forms from the other two polymorph forms. These peak positions, expressed in wavenumbers (cm"1) for the hydrochloride salt of polymorph form A are: Peak Positions In Wavenumbers (cm" ) for Polymorph Form A 762 636 921 959 1393 1597 2890 2982 and 3064.

Any of these key peaks, either alone or in any distinguishing combination, are sufficient to distinguish polymorph form A from the other two polymorph forms The characterizing peak positions expressed in wavenumbers (cm'1) for the hydrochloride salt of polymorph form B are: Peak Positions In Wavenumbers (cm'1) for Polymorph Form B 1245; 1380; 2963; 2993; 3027; and 3066. 11 PCT/U S 20 05/0294 20 Any of these key peaks, either alone or in any distinguishing combination, are sufficient to distinguish polymorph form B from the other two polymorph forms.

The characterizing peak positions expressed in wavenumbers (cm"1) for the hydrochloride salt of polymorph form C are: Peak Positions in Wavenumbers (cm"1) for Polymorph Form C 1059: 1094 1266 1343 1595 2900 2966 and 3070.

Any of these key peaks, either alone or in any distinguishing combination, are sufficient to distinguish polymorph form C from the other two polymorph forms In accordance with this invention, each of the crystalline polymorph forms of the acid addition salt (+)-l-(3,4-dichlorophenyl)-3-azabicyclo[3.I.0]hexane can be obtained substantially free of its other enantiomeric, geometric and polymorphic isomeric forms. The term "substantially free" of its other enantiomeric, geometric and polymorphic isomeric forms designates that the crystalline material is at least about 95% by weight pure in that it contains no more than about 5% w/w of its other enantiomeric, geometric and polymorphic isomeric forms.

In the past, preparation of acid addition salts of (+)-l-(3,4-dichlorophenyl)-3~ azabicyclo[3.1,0]hexane has resulted in a mixture of the A and B polymorph forms. This mixture constituted an approximately 50% by weight mixture of each polymorph which could not be easily separated. In addition, it has been found that there was some inter- conversion of polymorph forms A and B upon standing at ambient temperature or inter-conversion, upon heating, of this 50% mixture to form a mixture of polymorph forms A, B and C, However, these mixtures could not be easily separated. Therefore, the purified isomeric forms of these individual polymorph forms substantially free of its other enantiomeric, geometric and polymorphic isomeric forms could not be obtained.

In accordance with this invention, it has been discovered that polymorph forms A, B and C of (+)-l-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, particularly as hydrochloride acid addition salts, can each be prepared substantially free of its other 12 enantiomeric, geometric and polymorphic isomeric forms through re-crystallization of a mixture of the A and B polymorph forms produced in accordance with prior art procedures. Depending upon the particular solvent, conditions and concentrations of materials utilized to re-crystallize the mixture of polymorph forms A and B, one can 5 selectively produce the desired polymorph form of (+)-l-(3,4-dichlorophenyl)-3-azabicyclo[3,l,0]hexane, substantially free of its other enatiomeric, geometric and polymorphic isomers.

In preparing polymorph forms A and B substantially free of other polymorph forms, crystallization from a mixture of A and B is generally utilized. However, the 10 crystallization technique with regard to producing each of these polymorph forms substantially free of other polymorph forms is different. In preparing polymorph form A, which is the hemi-hydrate of the acid addition salt of (+)-l-(3,4-dichlorophenyl)~3-azabicyclo[3. LOjhexane, it is best to utilize a solvent medium to dissolve a solid containing polymorph form A such as a mixture of polymorph forms A and B in an 15 organic solvent which contains water. The preferred organic solvents that can be utilized in this procedure include lower alkanol solvents such as methanol, butanol, ethanol or isopropanol as well as other solvents such as acetone, dichloromethane and tetrahydrofiiran. In forming the purified polymorph form A substantially free of other polymorph forms, it is best to incorporate water in these solvents when preparing the 20 medium for crystallization, Once the solid, preferably a mixture of polymorph forms A and B, is dissolved in this medium, the solvent should be allowed to evaporate at room temperature over a long period of time while the solution is exposed to the atmosphere. Room temperature can constitute any temperature from about 15°C to 35°C. The evaporation can take place until all of the solvent medium is removed leaving the purified 25 crystals of polymorph form A, Preferably evaporation may be carried out naturally such as by slow evaporation. Depending upon the amount of the solution and its concentration, evaporation can take place over a period from three to fifteen days or longer until the solvent is completed evaporated leaving a dry solid crystalline residue which is polymorphic form A substantially free of other polymorph forms.

Polymorph form B is the anhydrous form of the acid addition salt of (+)-l-(3,4- dichlorophenyl)-3-azabicyclo[3.1.0]hexane. Polymorph form B of the acid addition salt of (+)-l-(3,4-dichlorophenyI)-3-azabicyclo[3,l .0]hexane can be prepared from a solid containing polymorph form A such as a mixture of polymorph forms A and B by 13 dissolving the polymorph form A or the mixture of polymorph forms A and B, preferably as the hydrochloride salt, utilizing anhydrous conditions. In accordance with a preferred embodiment of the invention, this solid is in crystalline form and is re-crystallized by utilizing an anhydrous organic solvent. Any of the organic solvents mentioned 5 hereinbefore can be utilized in their anhydrous form to produce polymorph form B. As set forth above, it is important that the re-crystallization take place under anhydrous conditions. In addition it is preferred that the removal of solvent to produce the crystalline form of polymorph B take place at elevated temperatures, i.e. from about 50°C to 80°C, under anhydrous conditions. After crystallization of polymorph B from the solvent 10 mixture, the solvent can be removed by filtering or decanting to leave polymorph form B substantially free of other polymorph fonns. In preparing the crystallizing medium prior to removal of the solvent, the formation of the crystallizing medium containing the mixture of forms A and B for re-crystallization can take place at elevated temperatures, if desired, i.e. from 50°C to 80°C.

Polymorph form C can be prepared from either polymorph form A or polymorph form B or mixtures thereof. Polymorph form C is prepared by extensive heating of either polymorph form A or polymorph form B, or mixtures thereof, at temperatures of at least 50°C, preferably from 60°C to 80°C. Heating can be continued until polymorph form C substantially free of other polymorph forms is formed. This heating can, if desired, take 20 place over long periods of time i.e. from 12 hours to 4 days of longer, until the polymorph forms of the starting material are converted to polymorph form C substantially free of other polymorph forms. The acid addition salt having the crystalline structure of polymorph form C substantially free of other polymorph forms is produced by extensive heating, usually not in the presence of a solvent, of the acid addition salts of polymorph 25 forms A and B. The preferred acid addition salt in this preparation is the hydrochloride acid addition salt form.

The techniques set forth above also allow for the preparation of mixtures of the individual polymorph forms of the acid addition salt of (+)-I-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane containing specific amounts of each of the polymorphs. In 30 particular, mixtures of polymorph form A and either polymorph form B or polymorph form C, polymorph form B and polymorph form C, and polymorph form A, polymorph form B and polymorph form C can be readily prepared with the desired amounts of each of the polymorphs. By way of example and not of limitation, a mixture of polymorph 14 foiin A and polymorph form B containing the desired amount of each polymorph can be prepared by subjecting polymorph form A substantially free of other polymorph forms and prepared as described above to the procedure for preparation of polymorph form B described above for the period of time needed to produce the desired amount of 5 polymorph form B. By way of further example, a mixture of polymorph form A and polymorph form C containing the desired amount of each polymorph can be prepared by subjecting polymorph form A substantially free of other polymorph forms and prepared as described above to the procedure for preparation of polymorph form C described above for the period of time needed to produce the desired amount of polymorph form C. By way of 10 additional example, a mixture of polymorph form B and polymorph form C containing the desired amount of each polymorph can be prepared by subjecting polymorph form B substantially free of other polymorph forms and prepared as described above to the procedure for preparation of polymorph form C described above for the period of time needed to produce the desired amount of polymorph form C. By way of further example, 15 mixtures of polymorph form A and either polymorph form B or polymorph form C, polymorph form B and polymorph form C, and polymorph form A, polymorph form B and polymorph form C containing the desired amount of each polymorph can be prepared by combining the desired polymorphs substantially free of other polymorph forms and prepared as described above so that the desired mixture is obtained.

Using the techniques set forth above, mixtures containing specific percentages of the individual polymorphic forms of the acid addition salt of (+)-l~(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane can be obtained, For example, mixtures containing from about 10% to about 10-20%, 20-35%, 35-50%, 50-70%, 70-85%, 85-95% and up to 95-99% or greater (by weight) of polymotph form A, with the remainder of the mixture being either 25 or both polymorph form B and polymorph form C, can be prepared, As another example, mixtures containing from about 10% to about 10-20%, 20-35%, 35-50%, 50-70%, 70-85%, 85-95% and up to 95-99% or greater (by weight) of polymorph form B, with the remainder of the mixture being either or both polymorph form A and polymorph form C, can be prepared. As a further example, mixtures containing from about 10% to about 10-30 20%, 20-35%, 35-50%, 50-70%, 70-85%, 85-95% and up to 95-99% or greater (by weight) of polymorph form C, with the remainder of the mixture being either or both polymorph form A and polymorph fonn B, can be prepared.

Additionally, many pharmacologically active organic compounds regularly crystallize incorporating second, foreign molecules, especially solvent molecules, into the crystal structure of the principal pharmacologically active compound to form pseudopolymorphs. When the second molecule is a solvent molecule, the 5 pseudopolymorphs can also be referred to as solvates. All of these additional forms of (+)-l-(3,4-dichlorophenyl)-3~azabicyc!o[3.1.Ojhexane are likewise contemplated by the present invention.

The polymorph forms A, B and C of the present invention can be prepared as acid addition salts formed from an acid and the basic nitrogen group of (+)-l-(3,4-10 dichlorophenyl)-3-azabtcyclo[3.1 .Ojhexane. Suitable acid addition salts are formed from acids, which form non-toxic salts, examples of which are hydrochloride, hydrobromide, hydroiodide, sulphate, hydrogen sulphate, nitrate, phosphate, and hydrogen phosphate, Examples of pharmaceutically acceptable addition salts include inorganic and organic acid addition salts. The pharmaceutically acceptable salts include, but are not limited to, metal 15 salts such as sodium salt, potassium salt, cesium salt and the like; alkaline earth metals such as calcium salt, magnesium salt and the like; organic amine salts such as triethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt and the like; organic acid salts such as acetate, citrate, lactate, succinate, tartrate, maleate, fumarate, mandelate, acetate, 20 dichloroacetate, trifluoroacetate, oxalate, formate and the like; sulfonates such as methanesulfonate, benzenesulfonate, p-toluenesulfonate and the like; and amino acid salts such as arginate, asparginate, glutamate, tartrate, gluconate and the like. The hydrochloride salt formed with hydrochloric acid is an exemplary useful salt.

The above individual polymorph forms and mixtures of polymorph forms of the 25 acid addition salt of (+)-l-(3,4-dichlorophenyl)-3-azabicyclo[3.1,0]hexane can be administered to human patients in the same manner as the previously known forms of (+)-l~(3,4-dichlorophenyl)-3-azabicyclo[3.1 .Ojhexane. Suitable routes of administration for the above individual polymorph forms and mixtures of polymorph forms of an acid addition salt of (+)-l-(3,4-dichlorophenyl)-3-azabicyclo[3.1 .Ojhexane include, but are not 30 limited to, oral, buccal, nasal, pulmonary, aerosol, topical, transdermal, mucosal, injectable, slow release and controlled release delivery, although various other known delivery routes, devices and methods can likewise be employed, Useful parenteral delivery methods include, but are not limited to, intravenous, intramuscular, 16 PCT/US2005/0294 29 intraperitoneal, intraspinal, intrathecal, intracerebroventricular, intraarterial, and subcutaneous injection.

Suitable effective unit dosage amounts for the above individual polymorphic forms and mixtures of polymorphic forms of an acid addition salt of (+)-l-(3,4-dichlorophenyl)-5 3-azabicyclo[3.1 .Ojhexane for mammalian subjects may range from about 1 to 1200 mg, 50 to 1000 mg, 75 to 900 mg, 100 to 800 mg, or 150 to 600 mg. In certain embodiments, the effective unit dosage will be selected within narrower ranges of, for example, about 10 to 25 mg, 30 to 50 mg, 75 to lOOmg, 100 to 150 mg, 150 to 250 mg or 250 to 500 mg. These and other effective unit dosage amounts may be administered in a single dose, or in the form of multiple daily, 10 weekly or monthly doses, for example in a dosing regimen comprising from about 1 to 5, or 2-3, doses administered per day, per week, or per month. In exemplary embodiments, dosages of about 10 to 25 mg, 30 to 50 mg, 75 to 100 mg, 100 to 200 (anticipated dosage strength) mg, or 250 to 500 mg, are administered one, two, three, or four times per day. In more detailed embodiments, dosages of about 50-75 mg, 100-150 mg, 150-200 mg, 250-400 mg, or 400-600 15 mg are administered once, twice daily or three times daily. In alternate embodiments, dosages are calculated based on body weight, and maybe administered, for example, in amounts from about 0.5mg/kg to about 30mg/kg per day, lmg/kg to about 15mg/kg per day, lmg/kg to about lOmg/kg per day, 2mg/kg to about 20mg/kg per day, 2mg/kg to about lOmg/kg per day or 3mg/kg to about 15mg/kg per day.

Using the routes and methods of administration and dosage amounts described hereinabove and the dosage forms described hereinbelow, the individual polymorph forms and mixtures of polymorph forms of the present invention can be used for the prevention and treatment of various diseases and conditions in humans. By way of example and not of limitation, in the case of depression, this is accomplished by administering to a patient 25 in need of said treatment who is suffering from depression a composition containing one of the above polymorph forms substantially free of other polymorph forms or mixtures of polymorphs and an inert carrier or diluent, said composition being administered in an effective amount to prevent or treat said depression. In accordance with this invention, (+)-l-(3,4-dichlorophenyl)-3-azabicyclo[3.1.Ojhexane, either as a polymorph form 30 substantially free of other polymorph forms or as a mixture of polymorph forms, is administered in an effective amount to prevent or treat depression. Any effective amount of such polymorph form substantially free of other polymorph forms or mixtures of polymorph forms needed to prevent or treat depression can be utilized in this composition. 17 PCT/US200S/029420 In general, in the case oral dosage forms, dosages of from about 0.5 mg/kg to about 5,0 mg/kg of body weight per day are used. However the amount of such polymorph form substantially free of other polymorph forms or mixtures of polymorph forms in the oral unit dose to be administered will depend to a large extent on the condition of depression 5 and the weight of the patient and of course be subject to the physician's judgment. In accordance with this invention, the oral unit dosage form containing the given polymorph form substantially free of other polymorph forms or mixtures of polymorph forms can be preferably administered at a dosage of from about 30 mg to 300 mg per day, more preferably from about 50 mg to about 200 mg per day, administered once or twice during 10 the day or as needed.

The present invention includes pharmaceutical dosage forms for the above individual polymorph forms and mixtures" of polymorph forms of an acid addition salt of (+)-1 -(3,4-dichlorophenyl)-3-azabicyclo[3,1,Ojhexane. Such pharmaceutical dosage forms may include one or more excipients or additives, including, without limitation, binders, 15 fillers, lubricants, emulsifiers, suspending agents, sweeteners, flavorings, preservatives, buffers, wetting agents, disintegrants, effervescent agents and other conventional excipients and additives. The compositions of the present invention can thus include any one or a combination of the following: a pharmaceutically acceptable carrier or excipient; other medicinal agcnt(s); pharmaceutical agent(s); adjuvants; buffers; preservatives; 20 diluents; and various other phannaceutical additives and agents known to those skilled in the art. These additional formulation additives and agents will often be biologically inactive and can be administered to patients without causing deleterious side effects or interactions with the active agent.

As previously noted, polymorph form A is a therrnodynamically stable polymorph of an 25 acid addition salt of (+)-l-(3,4-dichlorophenyl)-3-azabicyclo[3.1,Ojhexane. Therefore, it is preferred that polymorph form A be used in phannaceutical dosage forms without the presence of other geometrical, optical and polymorphic isomers of (+)-1 -(3,4-dichlorophenyl)-3-azabicyclo[3.1.Ojhexane. However, polymorph forms B and C can also be included in pharmaceutical product formulations with less positive results concerning formulation and 30 stability.

If desired, the individual polymorph forms or mixtures of polymorph forms of the present invention can be administered in a controlled release form by use of a slow release carrier, such as a hydrophilic, slow release polymer, Exemplary controlled release agents 18 WO 2006/023659 PCT/US2005/029420 in this context include, but are not limited to, hydroxypropyl methyl cellulose, having a viscosity in the range of about 100 cps to about 100,000 cps.

The individual polymorph forms or mixtures of polymorph forms of the present invention can be formulated and administered in oral dosage form, optionally in 5 combination with a carrier or other additive(s), Suitable carriers common to pharmaceutical formulation technology include, but are not limited to, microcrystalline cellulose, lactose, sucrose, fructose, glucose, dextrose, other sugars, di-basic calcium phosphate, calcium sulfate, cellulose, methylcellulose, cellulose derivatives, kaolin, mannitol, lactitol, maltitol, xylitol, sorbitol, other sugar alcohols, dry starch, dextrin, 10 maltodextrin, other polysaccharides, or mixtures thereof.

Exemplary oral unit dosage forms for use in the present invention include tablets, capsules, powders, solutions, syrups, suspensions and lozenges, which may be prepared by any conventional method of preparing pharmaceutical oral unit dosage forms. Oral unit dosage forms, such as tablets, may contain one or more of the conventional, 15 pharmaceutically acceptable additional formulation ingredients, including but not limited to, release modifying agents, glidants, compression aides, disintegrants, effervescent agents, lubricants, binders, diluents, flavors, flavor enhancers, sweeteners and preservatives. These ingredients are selected from a wide variety of excipients known in the pharmaceutical formulation art. Depending on the desired properties of the oral unit 20 dosage form, any number of ingredients may be selected alone or in combination for their known use in preparing such dosage forms as tablets.

Suitable lubricants include stearic acid, magnesium stearate, talc, calcium stearate, hydrogenated vegetable oils, sodium benzoate, leucine carbowax, magnesium lauryl sulfate, colloidal silicon dioxide and glyceryl monostearate. Suitable glidants include 25 colloidal silica, fumed silicon dioxide, silica, talc, fumed silica, gypsum and glyceryl monostearate. Substances which may be used for coating include hydroxypropyl cellulose, titanium oxide, talc, sweeteners and colorants. The aforementioned effervescent agents and disintegrants are useful in the formulation of rapidly disintegrating tablets known to those skilled in the art. .These typically disintegrate in the mouth in less than one 30 minute, and often in less than thirty seconds. By effervescent agent is meant a couple, typically an organic acid and a carbonate or bicarbonate, The following examples illustrate certain embodiments of the present invention, and are not to be construed as limiting the present disclosure. 19 EXAMPLES Example 1 This example is directed to preparing the hydrochloride salt of (+)-l-(3,4 5 dichlorophenyl)-3-azabicyclo[3.1.0] hexane from the free base of (+)-l- (3,4dichlorophenyl)-3-azabicyclo[3.1;0] hexane and to demonstrate that this method produced a mixture of polymorph form A and polymorph form B, Approximately 250 mg of the free base of (+)-l-(3, 4-dichlorophenyl)-3-azabicyc]o[3.1.0] hexane was dissolved in 400 mL 95:5 (v/v) hexane/isopropanol (with 10 0.05% diethylamine). The solution was evaporated under a nitrogen stream on a stir plate set at approximately 70°C, concentrating the sample to a clear gel. This gel was dissolved in 50 mL ethyl acetate and dried under a nitrogen stream, yielding a thin, clear to off-white (tint of yellow), milky residue, This residue was dissolved in 7 mL diethyl ether, and 7 mL HCI saturated diethyl ether was added; chunks of white solid were precipitated 15 immediately. This solid was recovered through vacuum filtration and washed with 19 mL diethyl ether. The filtered solid appeared dry. The (+)-l-(3,4-dichlorophoyl)~3-azabicyclo[3.1.0] hexane hydrochloride salt was recovered (162.5 mg), resulting in a yield of 55.7%.

XRPD analysis and Raman spectroscopy performed as described above indicated 20 that both the starting material (free base) and end product (hydrochloride salt) constituted a mixture of polymorph form A and polymorph form B. Both the starting material and end product were observed to contain approximately 50% (by weight) of each polymorph. There was only a minor difference in the % of these polymorphs in the starting material and in the final product, Example 2 Stability Studies on the End Product of Example 1 Duplicate samples of the hydrochloride salt of (+)-l-(3,4dichlorophenyI)-3-azabicyclo[3.1.0] hexane produced in Example 1 and containing a 50% (by weight) mixture of polymorph form A and polymorph form B were placed on informal stability to 30 test storage in desiccators placed at ambient temperature and at 50°C in a programmable heating bloc. The samples were examined after 1 week and while both samples contained mixtures of polymorph form A and polymorph form B, the ratios observed showed some conversion of forms. The mixture subjected to ambient temperature was observed to contain 40% (by weigh) of polymorph form A and 60% (by weight) of polymorph form B WO 2006/023659 PCT/US2005/029420 (as determined by XPRD analysis?). This result was confirmed by Raman spectroscopy, Subsequent XRPD analysis of the sample stored in a 50°C programmable heating block showed about 50% (by weight) of polymorph form A and 50% (by weight) of polymorph form C after 17 days of storage.

Example 3 Method of Manufacture of (+)-l-(3,4-dichiorophenyi)-3-azabicyclo[3.1,0] hexane hydrochloride Step 1: Synthesis of a-bromo-3.4-dichlorophenvlacctic acid methyl ester 10 100 kg 3,4-dichlorophenylacetonitrile was added in portions over 1.25 hours to a mixture of 12 kg water and 140 kg 98% sulfuric acid. Exotherm was aliowed to 65°C maximum, and the reaction mix was maintained at 60-65°C for 30 minutes. After cooling to 50°C, 80 kg methanol was slowly added over 25-30 minutes. The mixture was warmed to 92-98°C, and maintained at this temperature for an additional three hours. After cooling to 35°C, the reaction mixture was quenched into an agitated mixture (precooled to % 0-5°C) of 150 L ethylene dichloride and 250 L water. The reactor and lines were washed with water into the quench mix, which was agitated 5 minutes and allowed to stratify. The lower organic phase was separated, and the aqueous phase washed with 2 x 150 L ethylene dichloride. The combined organic phases were washed with 100 L water and then with 20 aqueous sodium carbonate (3 kg sodium carbonate in 100 L water). The solution of crude ester was azeotropically "dried" in vacuo at 60-620C, resulting in the collection of 100 L ethylene dichloride. A theoretical yield was assumed without isolation and the solution was used "as is" in the following bromination reaction.

A mixture of the solution (line-frltered) of crude methyl 3,4-dichlorophenylacetate 25 (from above) and 88 kg 1,3-dibromo-l,3-dlmethylhydantoin (DBDMH) was warmed to 80°C, and a solution of 2.5 kg VAZO 52 in 15 L ethylene dichloride was added portion wise over a 5 hour period, maintaining 85-90°C (under reflux). An additional 8.8 kg DBDMH was then added, and a solution of 0.5 kg VAZO 52 in 4 L ethylene dichloride was added portion wise over a 2.5 hour period, maintaining 85-90°C (under reflux). 30 Heating was then discontinued, and 350 L water was added with agitation. The mixture was allowed to stratify, the lower organic phase was separated and the aqueous phase was washed with 50 L ethylene dichloride. The combined organic phases were washed with aqueous thiosulfate (5.0 kg sodium thiosulfate in 150 L water), aqueous sodium carbonate (2.5 kg sodium carbonate in 150 L water), and dilute hydrochloric acid (5.4 L 32% HCI in 21 100 L water). The organic phase was line-filtered and distilled in vacuo to "dryness" (full vacuum to 83°C). Residual ethylene dichloride was chased with 20 kg toluene (full vacuum at 83°C). The crude a-bromo-3,4-dichlorophenylacetic acid methyl ester was taken up in 82 kg toluene, cooled to 40°C, and discharged to steel drums. The product was 5 not isolated, and was used "as is" in Step 2, A theoretical yield was assumed for calculation purposes.

Step 2: Synthesis of l-f3.4-dlchlorophenvl-1.2-cvcloprooanc-dicarboxvlic acid dimethyl ester The crude a-bromo-3,4-dichlorophenylacetic acid methyl ester from Step 1 was mixed well with 55,6 kg methyl acrylate, and then the mixture was added to a precooled (-2°C) mixture of 54,4 kg potassium methoxide in 500 L toluene (argon blanket) over 5.5 hours with good agitation and maintained at < +10°C. After standing overnight (5 psig argon) with brine cooling (-5°C), the cold reaction mixture was quenched into a mix of 15 250 L water and 30 kg 32% hydrochloric acid with good agitation, 200 L water and 2.5 kg potassium carbonate were added to the mixture with good agitation for an additional 30 minutes. After stratification, the lower aqueous phase was separated, and 150 L water and 1,0 kg potassium carbonate were added to the organic phase. The mixture was agitated 5 minutes and stratified. The lower aqueous phase was separated and discarded, as well as 20 the interfacial emulsion, and the organic phase was washed with 100 L water containing 1 L 32% hydrochloric acid. After stratification and separation of the lower aqueous phase, the organic phase was line-filtered and distilled in vacuo to "dryness" (full vacuum at 65°C). To the hot residue was added 70 kg methanol with agitation. The mix was cooled (seeding at +10°C) to -5°C and maintained at this temperature overnight. The cold thick 25 suspension was suction-filtered (Nutsche), and the cake of l-(3,4-dichlorophenyl)-l,2-cyclopropane-dicarboxylic acid dimethyl ester was suction dried, washed with 2 x 20 L hexane, suction dried for 30 minutes and air-dried on paper (racks) for 2 days at ambient conditions.

To the methanolic liquors was added 50 kg caustic soda flake portion wise over 8 30 hours with good agitation, After gassing and the slow exotherm (60°C maximum) ceased, the heavy suspension was held at 50°C for 1 hour. 100 L isopropanol was slowly added over 10 minutes, and then the mixture was agitated slowly overnight at ambient conditions. The solids were suction-filtered (Nutsche) and reslurried with 80 L methanol. The resulting l-(3,4-dichiorophenyl)-l,2-cyclopropane-dicarboxylic acid disodium salt 22 was suctioned-filtered (Nutsche), washed with methanol (40 L), suction dried for 1 hour and air-dried on paper (racks).

Step 3: Synthesis of l-G.4-dichlorophenvl)-1.2-cvclopropane-dicarboxvlic acid A suspension of 42,0 kg l-(3,4-dichlorophenyl)-l,2-cyclopropane-dicarboxylic 5 acid disodium salt (from Step 2) and 120 L deionized water was warmed to 30-35°C, and the solution was line-filtered and neutralized with 30 kg 32% hydrochloric acid to precipitate the free dicarboxylic acid, 120 kg ethyl acetate was added, and the mix warmed to 40-50°C to effect solution, The lower aqueous phase was separated and washed with 20 kg ethyl acetate. The combined organic extracts were washed with 10 saturated sodium chloride (3 kg in 30 L water) and then distilled in vacuo to "dryness" (full vacuum to 70°C). 60 kg ethylene dichloride was added to the warm residue, and the solution cooled with slow agitation at-5°C overnight. Residual ethyl acetate was distilled (full vacuum to 43°C) to yield a thick suspension, which was then cooled with full vacuum to -5°C over a 2.5 hour period and then suction-filtered (Nutsche). The l-(3,4-15 dichlorophenyI)-l,2-cyclopropane-dicarboxylic acid cake was washed with cold ethylene dichloride (2x5 L), followed by ambient ethylene dichloride (4x5 L), The dicarboxylic acid product was suction dried for 15 minutes and air-dried on paper (racks).

A mixture of 31,0 kg l-(3,4-dich!orophenyl)-l,2-cyclopropane-dicarboxylic acid dimethyl ester (from Step 2), 40 L water, 35 kg methanol and 18.0 kg 50% caustic soda 20 was warmed to 70-75°C (under reflux) and maintained at 70-75t>C for 1.5 hours, 10 L water was then added, and the mixture was kept at 75-77°C for an additional 2 hours. Methanol was slowly distilled off in vacuo to 70°C to give a heavy suspension, which was then mixed with 80 L water to effect solution. The free dicarboxylic acid was precipitated with 31 kg of 32% hydrochloric acid and extracted with 100 kg ethyl acetate. The lower 25 aqueous phase was separated and washed with 20 kg ethyl acetate. The combined organic phases were washed with 50 L water, and then saturated aqueous sodium chloride. Distillation in vacuo to 80°C with full vacuum yielded a concentrate of 1-(3,4-dichlorophenyl)-! ,2-cyclopropane-dicarboxylic acid, which was used "as is" for the next step, cyclization to the imide. A quantitative yield from the diester was assumed for 30 calculation purposes.

Step 4: Synthesis and Recrvstallization of l-(3.4-dichlorophenvlV3-azabicvcloj"3.l.O] hexane-2,4-dione 23 The slurry of l-(3,4-dichlorophenyl)-l,2-cyclopropane-dicarboxylic acid (from Step 3) was added to 45.6 kg warm (68°C) formamide, and residual ethyl acetate was distilled with full vacuum at 68-73°C, An additional 14.4 kg formamide was added to the mixture, followed by 11.2 kg of the dicarboxylic acid (derived from the disodium salt, 5 Step 3). An argon blanket on the mixture was maintained for the following operation. The mixture was agitated 15 minutes at 73-75°C to effect a complete solution, and then heated over a 1 hour period to 140-145°C and maintained at this temperature for an additional 2.25 hours. Heating was discontinued, and the mixture was cooled to 70°C and 10 L water containing 20 ml 32% HCI was slowly added over 30 minutes. The mixture 10 was seeded and crystallization commenced. An additional 20 L water was slowly added to the heavy suspension over a 2 hour period. After standing overnight at ambient conditions, the mixture was agitated for 1,25 hours at ambient temperature and then suction-filtered (Nutsche). The cake of crude l-(3,4-dichlorophenyl)-3-azabicyclo-[3.1.0]hexane~2,4-dione was washed with water (3 x 20 L), suction dried for 30 minutes 15 and air-dried on paper (racks) for 2 days under ambient conditions.

A mixture of 37 kg crude, damp l-(3,4-dichlorophenyl)-3-azabicyclo-[3,1.0]hexane-2,4-dione (from Step 4, above) and 120 L toluene was wanned to 75-80°C to effect solution. After stratification and separation of the residual water (3.3 kg), 1 kg Darco G-60 activated carbon (American Norit Co.) (suspended in 5 L toluene) was added. 20 The mixture was agitated at 80°C for 30 minutes and then pressure filtered through a preheated Sparkler (precoated with filteraid), polishing with a 10 |im in-line filter. The clear light yellow solution was concentrated in vacuo at 75-80°C to 100 L final volume and slowly cooled, with seeding at 70°C. The heavy crystalline suspension was cooled to -5°C, held 30 minutes at this temperature and suction-filtered (Nutsche). The cake of 25 purified 1 -(3,4-dichlorophenyl)-3-azabicyclo-[3.1,0]hexane-2,4-dione was washed with 2 x 10 L cold (-10°C) toluene, and then 2 x 20 L hexane. After suction drying for 30 minutes, the 2,4-dione product was dried in vacuo (< 62°C).

Step 5: Synthesis and Purification of (jbVl-(3.4-Dichloroohenv]V3-azabicvclo [3.1.0"jhexane hydrochloride 30 BH3-THF complex is charged into a 2 L addition funnel (9 x 2 L, then 1 x 1.5 L) and drained into a 50 L flask. 24 WO 2006/023659 PCT/US2005/029420 1000 g of (±)-l-(3,4 dichlorophenyl)-3-azabicyclo[3.1.0]-hexane-2,4-dione is dissolved in 2 L of THF and added to the BH3-THF dropwise over a period of 2 hours. The reaction mixture is heated to reflux and held at this temperature overnight. The mixture is then cooled to <10°C, adjusted to pH 2 with the addition of 1200 mL of 6N 5 HCI dropwise at <20°C, and stirred for a minimum of 1 hour.

The reaction mixture is then transferred to a 10 L Buchi flask, concentrated to a milky white paste, and transferred again to a 5-gallon container. The mixture is diluted with 4 L of cold water and adjusted to pH 10 with 2000 mL of a 25% sodium hydroxide solution. A temperature of <20°C is maintained. Following this, 4.5 L of ethyl acetate is 10 added and the mixture is stirred for 15 minutes. The solution is then filtered through a 10 inch funnel with a filter cloth and washed with ethyl acetate (2 x 250 mL).

The filtrate is then transferred into a 40 L separatory funnel and the phases are allowed to separate. Each phase is then drained into separate 5-gallon containers. The aqueous layer is returned to the 40 L separatory funnel and extracted with ethyl acetate (2 15 x2L). The organic phases are combined. The aqueous layer is discarded. 250 g of magnesium sulfate and 250 g of charcoal are added to the combined organics and the mixture is stirred well. The solution is then filtered through an 18.5 cm funnel using a filter pad and washed with ethyl acetate (2 x 250 mL). The filtrate is then transferred to a 10 L Buchi flask and concentrated to dryness. The resulting yellowish oil 20 is diluted with ethyl acetate (2.25 mL/g).

HCI gas is bubbled through a 12 L flask containing 10 L of ethyl acetate to make an approximately 2.3 M solution of HCI/ethyl acetate. This HCI/ethyl acetate solution is added to the oil dropwise at a rate that maintains a temperature of <20°C using an ice/water bath. The solution is then stirred at <10°C for a minimum of 2 hours in the 25 ice/water bath. The material is chilled in a cold room overnight.

The resulting solids are then filtered through a 10 inch funnel utilizing a filter cloth and washed with ethyl acetate (2 x 200 mL) and ethyl ether (3 x 500 mL). The product, crude (±)-l-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]-hexane hydrochloride, is then transferred to Pyrex drying trays and dried for 4 hours, 1900 g of crude (±)-l-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane hydrochloride from above, and 15.2 L of isopropyl alcohol are charged to a 22 L flask. The mixture is heated to dissolve all material.

WO 2006/023659 PCT/US2005/029420 The material is then filtered through a 18.5 cm funnel utilizing a filter pad and transferred to a 22 L flask. The solution is then stirred at room temperature for 1 hour. The solution is then chilled to 4°C with an ice/water bath and stirred for 3.75 hours. The product is then placed in a cold room overnight.

The solids are then filtered through a 13 inch filter using a filter cloth and washed with ethyl ether (3 x 633 mL). The product is then air dried for 2 hours.

The product, pure (±)-l-(3,4-dichlorophenyl)-3-azabicyclo[3.1,Ojhexane hydrochloride, is transferred to clean Pyrex drying trays and dried to constant weight.

Step 6: Resolution of (±V l-(S3.4-dichlorophenvD-3-azabicvcIorr3.1 .Olhexane 10 hydrochloride into (+Vl-f3.4-dichlorophenvlV3-a2ablcvclo|'3.1.Olhexane hydrochloride In a 50 gallon reactor containing 60 L of 15% NaOH, 13.6 kg of pure (dfc)-l-(3,4dichlorophenyl)-3-azabicyclo[3,l.Ojhexane hydrochloride (from Step 5, above) is added while keeping the temperature constant at approximately 20°C. Once the addition of (±)-l-(3,4-dichlorophenyl)~3-azabicyclo[3.1.Ojhexane hydrochloride is complete, the 15 reaction mixture is allowed to stir at room temperature for a minimum of 8 hours. 40 L of ethyl acetate is added to the reactor and the two phase mixture is stirred until a clear solution is obtained (approximately 2 hours). The phases are allowed to separate and the organic layer is transferred to another 50 gallon reactor. The remaining aqueous layer is extracted with ethyl acetate (6x6 L). All organic phases are combined 20 into the 50-gallon reactor. The organic phase is dried and decolorized by the addition of 4000 g magnesium sulfate and 250 g of charcoal. The mixture is then filtered through an in-line filter. The filtrate is transferred via in-line filter to a 50-gallon reactor.

In a separate 50-gallon reactor, 23,230 g of L-(-)~dibenzoyl tartaric acid is dissolved with stirring (approximately 30 minutes) in 71 L of methanol. The dissolution is 25 assisted with heating if necessary, The L-(-)-dibenzoyl tartaric acid solution in methanol is added via addition funnel to the reactor containing the filtrate, over a period of approximately 1 hour, maintaining the temperature at 15-25°C. After the addition is complete the mixture is stirred for approximately 16 hours at 15-25°C. Following stirring, 50 L of methanol is added to the 30 mixture and it is stirred again for 30 additional minutes. The resulting solids are filtered onto a plate filter. The solids are then washed with methanol (3 x 5 L) and pressed dry. The crude solids are weighed and transferred to a 50-gallon reactor to which 80 L of methanol is added. The mixture is heated to reflux and stirred at reflux for approximately 26 minutes. The mixture is then cooled to 15-20°C and stirred at this temperature for approximately 2 hours. The resulting solids are filtered onto a plate filter using a polypropylene filter cloth. The cake is washed with methanol (3 x 5 L) and pressed dry, The solids are transferred to a tarred 5-gallon container and weighed (yield ~ 20 kg). 5 The solids are then added (over a period of approximately 1 hour) to a 50 gallon reactor vessel containing 60 L of 15% NaOH while maintaining the temperature at approximately 20°C. Once the addition of the solids is complete the reaction mixture is stirred for approximately 19 hours. 40 L of ethyl acetate is charged to the reactor, while maintaining the temperature 10 at < 35DC and the two phase mixture is stirred until a clear solution is obtained (approximately 2 hours). The phases are allowed to separate and the organic layer is transferred to another 50 gallon reactor. The remaining aqueous layer is extracted with ethyl acetate (6x6 L), All organic phases are combined into the 50-gallon reactor. 5000 g of magnesium sulfate is then added to the organic phase. The mixture is then filtered 15 through an in-line filter. The filtrate is transferred via in-line filter to a 50-gallon reactor. The filtrate is concentrated to a total volume of 20-30 L, In a 22 L three neck round bottom flask, HCI gas is bubbled through 12 L of ethyl acetate to make an approximately 2.3 M solution of HCI/ethyl acetate. After titration assay, the solution is adjusted to exactly 2,3 M by adding either ethyl acetate or HCI gas. 20 8.2 L of the 2.3 M solution of HCI/ethyl acetate is added (over a period of approx. 1.5 hours) to the filtrate (above), maintaining the temperature at < 20°C and ensuring that apH of 2 is obtained. Once the addition is complete, the mixture is stirred at 0 to -5°C for a period of 16 hours, The resulting solids, crude (+)-l-(3,4-dichlorophenyl)-3-azabicyclo[3.1.Ojhexane 25 hydrochloride, are filtered onto a plate filter using a polypropylene filter cloth. The solids are then washed with ethyl acetate (2x2 L), acetone (2 x 2 L) and ethyl ether (2 x 2 L) and dried under vacuum. The material is transferred to a tarred 5-gallon polyethylene container and weighed.

Step 6a: Recrvstallization of (+Vl-(3.4-dichloroPhenviV3-azabicvclor3.1 .Olhexane 30 hydrochloride from isooropanol The solids (from Step 6, above) are transferred to a 50-gallon reactor and isopropanol is added (8-10 mL/g of solid). The mixture is heated to reflux. The solution is filtered through an in-line filter into another 50 gallon reactor. The solution is cooled to 0 to -5°C and maintained at this temperature with stirring for approximately 2 hours. The resulting solids are filtered onto a plate filter using a polypropylene filter cloth. The solids are then washed with ethyl acetate (2 x 2 L), acetone (2 x 2 L) and ethyl ether (2 x 2 L). The solids are dried under vacuum.

The product, (+)-l-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane hydrochloride, is transferred into clean, tarred drying tray(s). The tray(s) are placed in a clean, vacuum drying oven. The product is dried at 50°C to constant weight. The material is dried for a minimum of 12 hours at < 10mm Hg. This product was a mixture of polymorph form A and polymorph form B, with each polymorph present in the mixture in an amount of about 10 50% by weight. This product was used as the starting material for Examples 4 through 8 below.

Example 4 The 50% by weight mixture of polymorph form A and polymorph form B of the 15 hydrochloride salt of (+)-l-(3,4-dichlorophenyl)-3-azabicyclo[3! ,0]hexane (54 mg) was dissolved in 12 ml of acetonitrile and water. Approximately half of this stock solution was then filtered through a 0.2:m nylon syringe filter into a clean vial. The vial was covered with aluminum foil punctured with a pinhole and left in a fume hood under ambient conditions for slow evaporation. After allowing the solvent in the vial to evaporate, which 20 occunred in about four days, a crystal residue was obtained which was the pure polymorph form A form of the hydrochloride salt of (+)-l-(3, 4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane as demonstrated by Raman spectroscopy and XRPD analysis as described above The same pure crystalline form was also obtained with other solvents prepared 25 using the same method, such as acetone, 2-butanoI, dichloromethane, ethanol, methanol, nitromethane, isopropanol and tetrahydrofuran. These solvents also contained water.

Example 5 68 mg of the 50% by weight mixture of polymorph form A and polymorph form B 30 of the hydrochloride salt of(+)-l- (3,4-dichlorophenyl)-3-azabicyclo[3.1,0]hexane was dissolved in 3.4 ml of ethyl ether:ethanol (1:1 ratio) solvent mixture. The resulted solution was filtered through a 0.2:m nylon syringe filter into a clean vial. Solid samples were collected by rotary evaporation of the solvents under vacuum. The solids were than dried under vacuum at ambient temperature to produce pure polymorph form B crystals of the 28 hydrochloride salt of (+)-l-(3,4-dichIorophenyl)-3-azabicyclo[3.1.Ojhexane as demonstrated by Raman spectroscopy and XRPD analysis as described above.

Example 6 51 mg of the 50% by weight mixture of polymorph form A and polymorph form B of the hydrochloride salt of (+)-l-(3,4-dichioropheny!)-3-azabicyclo[3.1.Ojhexane was weighed into a vial. The vial was covered with aluminum foil perforated with pinholes and placed in an oven at 80°C for 4 days to produce the pure polymorph C crystals of the hydrochloride salt of (+)-l-(3, 4-dichlorophenyl)-3-azabicyclo[3.1.Ojhexane as 10 demonstrated by Raman spectroscopy and XRPD analysis as described above.

Example 7 Preparation of Polymorph Form B 40 mg samples of the 50% by weight mixture of polymorph form A and 15 polymorph form B of the hydrochloride salt of (-t-)-l -(3,4-dichlorophenyl)-3- azabicyclo[3.1 .Ojhexane were mixed with 0.5 mL of anhydrous acetonitrile to produce a concentration of about 80-100 mg/mL and the resulting samples were stirred at various temperatures between 50°C and 80°C for various periods of time (some for 4 days and 6 days at about 50°C and some for 1 day at about 80°C). The resulting samples were each 20 mixtures of a clear liquid and some solid. The clear liquid was decanted off, and the remaining solid was vacuum dried at ambient temperature for 1 hour to 2 days (50°C sample), or 6 days (80°C sample) to afford pure crystalline polymorph form B. All samples produced the pure polymorph form B crystals of the hydrochloride salt of (+)-l-(3, 4-dichlorophenyl)~3-azabicyclo[3,l.Ojhexane as demonstrated by Raman spectroscopy 25 and XRPD analysis as described above.

Example 8 Preparation of Polymorph Form A m« samples of the 50% by weight mixture of polymorph form A and 30 polymorph form B of the hydrochloride salt of (+)-1 -(3,4-dichlorophenyl)-3- azabicyclo[3.1 .Ojhexane were dissolved in 0.5 ml of aqueous ethanol. Other samples were prepared by dissolving 20 mg of this mixture in 0.5 mL of water. Both solutions were filtered through a 0.2 micron nylon filter. Both filtered solutions were then allowed to evaporate under ambient conditions, some samples partially covered and other samples 29

Claims (69)

WO 2006/023659 PCT/US2005/029420 completely uncovered. After 6 days, both the uncovered and partially covered ethanol solution samples evaporated. After 7 days, the uncovered water solutions evaporated. After 15 days, the partially covered water solutions evaporated. For each sample, after the solvent (either aqueous ethanol or water) evaporated completely, 20 mg of dry solid 5 residue was left. The solid in all samples thus produced was the pure polymorph form A crystals of the hydrochloride salt of (-f)-l-(3,4-dichlorophenyl)-3-azabicyclo[3.1,Ojhexane as demonstrated by Raman spectroscopy and XRPD analysis as described above. 30 RECEIVED at IPONZ on 18 May 2012 The claims defining the invention are as follows: 10 15 20 25 30 35

1. A composition comprising an acid addition salt of (+)-1 -(3,4-dichlorophenyl)-3 -azabicyclo[3.1.Ojhexane enriched for a selected polymorphic form of said acid addition salt of (+)-1 -(3,4-dichlorophenyl)-3-azabicyclo[3.1 .Ojhexane selected from: Polymorph A exhibiting an X-ray powder diffraction pattern as measured at crystal sizes of from about 10 to 40 microns characterized by distinguishing peaks at one or more of and at about the following °20 (degree) values: 17.14 19.62 21.96 24.52; and 26.74 Polymorph B exhibiting an X-ray powder diffraction pattern as measured at crystal sizes of from about 10 to 40 microns characterized by distinguishing peaks at one or more of and at about the following °20 (degree) values: 15.58 17.52 21.35 23.04 25.43; and 30.72; and Polymorph C exhibiting an X-ray powder diffraction pattern as measured at crystal sizes of from about 10 to 40 microns characterized by distinguishing peaks at one or more of and at about the following °20 (degree) values: 13.34 17.64 20.07 21.32 22.97 24.86. 26.32; and 27.90, wherein said composition is enriched to contain at least 70-80% of said Polymorph A, Polymorph B, or Polymorph C, by weight.

2. The composition of claim 1, wherein the composition contains no more than about 5% w/w of Polymorphs B and C.

3. The composition of claim 2 wherein Polymorph A is a hydrochloride salt. 31 RECEIVED at IPONZ on 18 May 2012

4. The composition of claim 3 wherein the X-ray powder diffraction pattern of polymorph A, as measured at crystal sizes of from about 10 to 40 microns, exhibits peaks at all of and at about the following °20 (degree) values: 5 17.14; 19.62; 21.96; 24.52; and 10 26.74.

5. The composition of claim 1, wherein the composition contains no more than about 5% w/w of Polymorphs A and C. 15

6. The composition of claim 5 wherein Polymorph B is a hydrochloride salt.

7. The composition of claim 6 wherein the X-ray powder diffraction pattern of polymorph, B, as measured at crystal sizes of from about 10 to 40 microns, exhibits peaks at all of and at about the following °20 (degree) values: 20 15.58; 17.52; 21.35; 23.04; 25.43; 25 and 30.72.

8. The composition of claim 1, wherein the composition contains no more than about 5% w/w of Polymorphs A and B. 30

9. The composition of claim 8 wherein Polymorph C is a hydrochloride salt.

10. The composition of claim 9 wherein the X-ray powder diffraction pattern of polymorph C, as measured at crystal sizes of from about 10 to 40 microns, exhibits peaks at all of and at about the following °20 (degree) values: 35 13.34; 17.64; 20.07; 21.32; 22.97; 32 RECEIVED at IPONZ on 18 May 2012 24.86; 26.32; and 27.90. 5

11. A composition comprising an acid addition salt of (+)-l -(3,4-dichlorophenyl)-3- azabicyclo[3.1.0]hexane enriched for a selected polymorphic form of said acid addition salt of (+)-1 -(3,4-dichlorophenyl)-3-azabicyclo[3.1,0]hexane selected from: Polymorph A exhibiting a Raman spectrum characterized by distinguishing peaks at 10 one or more of and at about the following wavenumbers (cm-1): 762 836 921 959 15 1393 1597 2890. 2982;and 3064 20 Polymorph B exhibiting a Raman spectrum characterized by distinguishing peaks at one or more of and at about the following wavenumbers (cm-1): 1245; 1380; 2963; 25 2993; 3027; and 3066;and Polymorph C exhibiting a Raman spectrum characterized by distinguishing peaks at one or more of and at about the following wavenumbers (cm-1): 30 1059 1094 1266 1343 1595 35 2966 2900;and 3070, wherein said composition is enriched to contain at least 70-80% of said Polymorph A, Polymorph B, or Polymorph C, by weight. 40

12. The composition of claim 11, wherein the composition contains no more than about 5% w/w of Polymorphs B and C. 33 RECEIVED at IPONZ on 18 May 2012

13. The composition of claim 12 wherein Polymorph A is a hydrochloride salt.

14. The composition of claim 13 wherein the Raman spectrum of polymorph A exhibits peaks at all of and at about the following wavenumbers (cm"1): 5 762; 836; 921; 959; 1393; 10 1597; 2890; 2982; and 3064. 15

15. The composition of claim 11, wherein the composition contains no more than about 5% w/w of Polymorphs A and C.

16. The composition of claim 15 wherein Polymorph B is a hydrochloride salt. 20

17. The composition of claim 16 wherein the Raman spectrum of polymorph B exhibits peaks at all of and at about the following wavenumbers (cm-1): 1245; 1380; 2963; 2993; 3027; and 3066. 30

18. The composition of claim 11, wherein the composition contains no more than about 5% w/w of Polymorphs A and B.

19. The composition of claim 18 wherein Polymorph C is a hydrochloride salt. 35

20. The composition of claim 19 wherein the Raman spectrum of polymoiph C exhibits peaks at all of and at about the following wavenumbers (cm-1): 1059; 1094; M 1266; 34 RECEIVED at IPONZ on 18 May 2012 1343; 1595; 2966; 2900; 5 and 3070.

21. A method of producing polymorph form A of an acid addition salt of (+) -1- (3,4-dichlorophenyl)-3-azabicyclo [3.1.0] hexane in crystalline form exhibiting at least one selected 10 from the group consisting of an X-ray powder diffraction pattern as defined in claim 1 and a Raman spectrum as defined in claim 11, substantially free of other geometric, optical and polymorphic isomers thereof comprising dissolving a solid containing one or more polymorphs of the acid addition salt of (+) -1- (3,4-dichlorophenyl)-3-azabicyclo [3.1.0] other than polymorph form A in a solvent medium containing water and allowing said solvent 15 medium to evaporate at a temperature of from about 15°C to 35°C while exposed to the atmosphere to remove said solvent medium and produce said polymorph fonn A in crystalline form.

22. The method of claim 21 wherein said solid is a mixture of polymorph forms A and B 20 of an acid addition salt of (+) -1- (3,4-dichlorophenyI)-3-azabicyclo [3.1.0] hexane.

23. The method of claim 22 wherein said acid addition salt is a hydrochloride salt.

24. The method of any one of claims 21-23 wherein said solvent medium contains a 25 lower alkanol.

25. The method of any one of claims 21-24 wherein the evaporation takes place over a period of at least 4 hours until said solvent medium evaporates. 30

26. Polymorph form A in crystalline form exhibiting at least one selected from the group consisting of an X-ray powder diffraction pattern as defined in claim 1 and a Raman spectrum as defined in claim 11, produced in accordance with the method of any one of claims 21-25.

27. A method of producing polymorph form B of an acid addition salt of (+) -1 - (3, 4-35 dichlorophenyl)-3-azabicyelo [3.1.0] hexane in crystalline form exhibiting at least one selected 35 RECEIVED at IPONZ on 18 May 2012 from the group consisting of an X-ray powder diffraction pattern as defined in claim 1 and a Raman spectrum as defined in claim 11, substantially free of other geometric, optical and polymorphic isomers thereof comprising dissolving a solid containing one or more polymorphs of the acid addition salt of (+) -1- (3,4-dichlorophenyl)-3-azabicyclo [3.1.0] 5 other than polymorph form B in an anhydrous organic solvent and crystallizing from said solvent under anhydrous conditions at temperatures of from about 50°C to 85°C said polymorph form B in crystalline form.

28. The method of claim 27 wherein said acid addition salt is a hydrochloride salt. 10

29. The method of claim 27 or 28 wherein said solid is a mixture of polymorph forms A and B of an acid addition salt of (+) -1- (3, 4-dichlorophenyl)-3-azabicyclo [3.1.0] hexane.

30. Polymorph form B in crystalline form exhibiting at least one selected from the group 15 consisting of an X-ray powder diffraction pattern as defined in claim 1 and a Raman spectrum as defined in claim 11,produced in accordance with the method of any one of claims 27-29.

31. A method of producing polymorph form C of an acid addition salt of (+) - 1- (3, 4-dichlorophenyl)-3azabicyclo [3.1.0] hexane in crystalline form exhibiting at least one selected 20 from the group consisting of an X-ray powder diffraction pattern as defined in claim 1 and a Raman spectrum as defined in claim 11, substantially free of other geometric, optical and polymorphic isomers thereof comprising heating a solid containing one or more polymorphs of the acid addition salt of (+) -1- (3,4-dichlorophenyl)-3-azabicyclo [3.1.0] hexane other than polymorph form C to a temperature of at least 50°C until said polymorph form C in 25 crystalline form is produced.

32. The method of claim 31 wherein said acid addition salt is a hydrochloride salt.

33. The method of claim 31 or 32 wherein said solid is a mixture of polymorph forms A 30 and B of an acid addition salt of (+) -1- (3,4-dichlorophenyl)-3-azabicyclo [3 .1 .0] hexane.

34. The method of claim 31 or 32 wherein said solid is a mixture of polymorph forms A, B and C of an acid addition salt of (+) -1- (3,4-dichlorophenyl)-3-azabicyclo [3.1.0] hexane. 36 RECEIVED at IPONZ on 18 May 2012

35. Polymorph form C in crystalline form exhibiting at least one selected from the group consisting of an X-ray powder diffraction pattern as defined in claim 1 and a Raman spectrum as defined in claim 11, produced in accordance with the method of any one of claims 31-34. 5

36. A pharmaceutical composition in oral unit dosage form comprising solid polymorph form A of a pharmaceutically acceptable acid addition salt of (+) -1- (3,4-dichlorophenyl)-3-azabicyclo [3.1.0] hexane in crystalline form exhibiting at least one selected from the group consisting of an X-ray powder diffraction pattern as defined in claim 1 and a Raman spectrum 10 as defined in claim 11, substantially free of other geometric, optical and polymorphic isomers thereof and an inert pharmaceutically acceptable carrier or diluent.

37. The pharmaceutical composition of claim 36 wherein said pharmaceutically acceptable acid addition salt is a hydrochloride salt. 15

38. The oral unit dosage form of claim 37 wherein said polymorph form A in crystalline form is present in said oral unit dosage form in the amount of about 25 mg to about 300 mg.

39. The pharmaceutical composition of claim 38 wherein said oral unit dosage form is a 20 tablet or capsule.

40. A phannaceutical composition in oral unit dosage form comprising solid polymorph form B of a pharmaceutically acceptable acid addition salt of (+) -1- (3,4-dichlorophenyl)-3-azabicyclo [3.1.0] hexane in crystalline form exhibiting at least one selected from the group 25 consisting of an X-ray powder diffraction pattern as defined in claim 1 and a Raman spectrum as defined in claim 11, substantially free of other geometric, optical and polymorphic isomers thereof and an inert pharmaceutically acceptable carrier or diluent.

41. The pharmaceutical composition of claim 40 wherein said pharmaceutically 30 acceptable acid addition salt is a hydrochloride salt.

42. The oral unit dosage form of claim 41 wherein said polymorph form B in crystalline form is present in said oral unit dosage form in the amount of about 50 mg to about 200 mg. 37 RECEIVED at IPONZ on 18 May 2012

43. The pharmaceutical composition of claim 42 wherein said oral dosage form is a tablet or capsule. 5

44. A pharmaceutical composition in oral unit dosage form comprising solid polymorph form C of a pharmaceutically acceptable acid addition salt of (+) -1- (3, 4-dichlorophenyl)-3-azabicyclo [3.1.0] hexane in crystalline form exhibiting at least one selected from the group consisting of an X-ray powder diffraction pattern as defined in claim 1 and a Raman spectrum as defined in claim 11, substantially free of other geometric, optical and polymorphic isomers 10 thereof and an inert pharmaceutically acceptable carrier or diluent.

45. The pharmaceutical composition of claim 44 wherein said pharmaceutically acceptable acid addition salt is a hydrochloride salt. 15

46. The pharmaceutical composition of claim 45 wherein said oral dosage form is a tablet or capsule.

47. Use of a composition containing polymorph form A of a pharmaceutically acceptable acid addition salt of (+) - 1- (3, 4-dichlorophenyl)-3-azabicyclo [3.1.0] hexane in crystalline 20 form exhibiting at least one selected from the group consisting of an X-ray powder diffraction pattern as defined in claim 1 and a Raman spectrum as defined in claim 11, substantially free of other geometric, optical and polymorphic isomers thereof and an inert carrier or diluent for the manufacture of a medicament for the prevention or treatment of depression in a patient in need of said treatment comprising administering to said patient in ail effective ainount. 25

48. The use of claim 47 wherein said pharmaceutically acceptable salt is the hydrochloride salt.

49. The use of claim 48 wherein said polymorph form A is administered to the patient at 30 an oral dose of from about 0.5 mg/kg to about 5.0 mg/kg of body weight per day.

50. Use of a composition containing polymorph form B of a pharmaceutically acceptable acid addition salt of (+) -1- (3,4-dichlorophenyl)-3-azabicyclo [3.1.0] hexane in crystalline 38 RECEIVED at IPONZ on 18 May 2012 form exhibiting at least one selected from the group consisting of an X-ray powder diffraction pattern as defined in claim 1 and a Raman spectrum as defined in claim 11, substantially free of other geometric, optical and polymorphic isomers thereof and an inert carrier or diluent for the manufacture of a medicament for the prevention or treatment of depression in a patient in 5 need of said treatment comprising administering to said patient in an effective amount.

51. The use of claim 50 wherein said pharmaceutically acceptable salt is the hydrochloride salt. 10

52. The use of claim 51 wherein said polymorph form B is administered to the patient at an oral dose of from about 0.5 mg/kg to about 5.0 mg/kg of body weight per day.

53. Use of a composition containing polymorph form C of a pharmaceutically acceptable acid addition salt of (+) - 1- (3, 4-dichlorophenyl)-3-azabicyclo [3.1.0] hexane in crystalline 15 form exhibiting at least one selected from the group consisting of an X-ray powder diffraction pattern as defined in claim 1 and a Raman spectrum as defined in claim 11, substantially free of other geometric, optical and polymorphic isomers thereof and an inert carrier or diluent for the manufacture of a medicament for the prevention or treatment of depression in a patient in need of said treatment comprising administering to said patient in an effective amount. 20

54. The use of claim 53 wherein said pharmaceutically acceptable salt is the hydrochloride salt.

55. The use of claim 54 wherein said polymorph form C is administered to the patient at 25 an oral dose of from about 0.5 mg/kg to about 5.0 mg/kg of body weight per day.

56. A pharmaceutical composition comprising a mixture of polymorph form A and either or both polymorph form B and polymorph form C, wherein Polymorphs A, B and C are exhibiting at least one selected from the group consisting of an X-ray powder diffraction 30 pattern as defined in claim 1 and a Raman spectrum as defined in claim 11, of a pharmaceutically acceptable acid addition salt of (+) -1- (3,4-dichloro)-3-azabicyclo [3.1.0] hexane. 39 RECEIVED at IPONZ on 18 May 2012

57. The pharmaceutical composition according to claim 56 wherein the amount of polymorph form A ranges from about 10% to about 20% (by weight).

58. The pharmaceutical composition according to claim 56 wherein the amount of 5 polymorph form A ranges from about 20% to about 35% (by weight).

59. The pharmaceutical composition according to claim 56 wherein the amount of polymorph form A ranges from about 35% to about 50% (by weight). 10

60. The pharmaceutical composition according to claim 56 wherein the amount of polymorph form A ranges from about 50% to about 70% (by weight).

61. The pharmaceutical composition according to claim 56 wherein the amount of polymorph form A ranges from about 70% to about 85% (by weight). 15

62. The pharmaceutical composition according to claim 56 wherein the amount of polymorph form A ranges from about 85% to about 95% (by weight).

63. The pharmaceutical composition according to claim 56 wherein the amount of 20 polymorph form A ranges from about 95% to about 99% (by weight).

64. A pharmaceutical composition comprising a mixture of polymorph form B and either or both polymorph form A and polymorph form C, wherein Polymorphs A, B and C are exhibiting at least one selected from the group consisting of an X-ray powder diffraction 25 pattern as defined in claim 1 and a Raman spectrum as defined in claim 11, of a pharmaceutically acceptable acid addition salt of (+) -1- (3,4-dichloro)-3-azabicyclo [3.1.0] hexane.

65 . A pharmaceutical composition comprising a mixture of polymorph form C and either 30 or both polymorph form A and polymorph form B wherein Polymorphs A, B and C are exhibiting at least one selected from the group consisting of an X-ray powder diffraction pattern as defined in claim 1 and a Raman spectrum as defined in claim 11, of a 40 RECEIVED at IPONZ on 18 May 2012 pharmaceutically acceptable acid addition salt of (+) -1- (3,4-dichloro)-3-azabicyclo [3,1.0] hexane.

66. The composition of claim 1 or 11, substantially as hereinbefore described with 5 reference to any one of the Examples.

67. The method of any one of claims 21,27 or 31, substantially as hereinbefore described with reference to any one of the Examples. 10

68. The pharmaceutical composition of any one of claims 36,40,44,56,64 or 65, substantially as hereinbefore described with reference to any one of the Examples.

69. The use of any one of claims 47, 50 or 53, substantially as hereinbefore described with reference to any one of the Examples. 15 41